Akari Therapeutics Plc Net Income Loss

• Akari Therapeutics Plc showed an increase of +12.6% in Net Income Loss from 2024 to 2025.
• This data is from Akari Therapeutics Plc's annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2006 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 20 years of available data (2006 to 2025), Akari Therapeutics Plc's Net Income Loss has declined by 877.8%.
• Historical annual values: Fiscal year 2025: -$17.30 million | Fiscal year 2024: -$19.79 million | Fiscal year 2023: -$10.01 million | Fiscal year 2022: -$17.75 million | Fiscal year 2021: -$17.42 million | Fiscal year 2020: -$17.08 million | Fiscal year 2019: -$16.85 million | Fiscal year 2018: -$20.50 million | Fiscal year 2017: -$35.40 million | Fiscal year 2016: -$18.14 million | Fiscal year 2015: -$45.32 million | Fiscal year 2014: -$1.95 million | Fiscal year 2013: -$3.62 million | Fiscal year 2012: -$4.27 million | Fiscal year 2011: -$2.12 million | Fiscal year 2010: -$675.0 thousand | Fiscal year 2009: -$1.01 million | Fiscal year 2008: -$1.44 million | Fiscal year 2007: -$3.13 million | Fiscal year 2006: -$1.77 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026